Munich Reinsurance Co Stock Corp in Munich Purchases Shares of 13,816 Labcorp Holdings Inc. $LH

Munich Reinsurance Co Stock Corp in Munich acquired a new position in Labcorp Holdings Inc. (NYSE:LH) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 13,816 shares of the medical research company’s stock, valued at approximately $3,686,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of LH. JPL Wealth Management LLC acquired a new position in Labcorp in the 3rd quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Labcorp in the fourth quarter worth $26,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Labcorp in the fourth quarter worth $27,000. Eagle Bay Advisors LLC acquired a new position in Labcorp during the fourth quarter valued at $29,000. Finally, DV Equities LLC purchased a new stake in Labcorp in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analyst Ratings Changes

LH has been the topic of several analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Wall Street Zen downgraded Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Robert W. Baird set a $334.00 price target on shares of Labcorp in a research note on Friday, May 1st. Finally, Evercore reissued an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Labcorp currently has an average rating of “Moderate Buy” and an average price target of $308.00.

Insider Buying and Selling at Labcorp

In other news, EVP Kathryn W. Kyle sold 762 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the transaction, the executive vice president directly owned 3,813 shares of the company’s stock, valued at approximately $1,006,212.57. This trade represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the transaction, the executive vice president owned 6,746 shares in the company, valued at $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 6,991 shares of company stock worth $1,796,696. Corporate insiders own 0.84% of the company’s stock.

Labcorp Price Performance

NYSE:LH opened at $277.81 on Thursday. The stock has a 50 day moving average of $263.33 and a two-hundred day moving average of $266.83. Labcorp Holdings Inc. has a 12 month low of $241.81 and a 12 month high of $293.72. The firm has a market cap of $22.78 billion, a P/E ratio of 24.61, a price-to-earnings-growth ratio of 1.99 and a beta of 0.89. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, analysts expect that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.